Cabaletta Bio, Inc.
NASDAQ:CABABiotechnology
+$0.04 today
- Market cap
- $227.58M
- Beta
- 3.23
- P/E (TTM)
- -1.8
- EPS (TTM)
- -$1.57
Volume 4.13M
Average 3.33M
CABA Weighted Avg Shares
Average number of basic shares outstanding during the period, used to calculate basic EPS.
Cabaletta Bio, Inc.NASDAQ: CABA
Weighted Avg Shares · Q1 FY2026 · quarter ended Mar 2026
Weighted avg shares growth accelerates
Q1 FY2026 weighted avg shares of 112.03M shares rose 126.2% year over year, ahead of the +91.6% change in trailing-twelve-month weighted avg shares. Sequentially, it rose 9.5% from the prior quarter. Over 3 fiscal years it compounded at +51.6% a year.
Context
- Weighted avg shares increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +126.2% holds above the trailing-twelve-month pace of +91.6%.
Sources:Income StatementText generated from reported figures; not investment advice.
Weighted Avg Shares history
Shares · from the income statement
- Latest · FY2025
- 102.26M USD
- Year-over-year change
- +106.5%
- 4-year CAGR
- +41.2%
| Period | Period end | Weighted Avg Shares | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 102.26M | +106.5% |
| FY2024 | 2024-12-31 | 49.52M | +20.9% |
| FY2023 | 2023-12-31 | 40.95M | +39.5% |
| FY2022 | 2022-12-31 | 29.34M | +14.0% |
| FY2021 | 2021-12-31 | 25.74M | — |
Weighted Avg Shares vs competitors
How CABA compares with its peers on the latest reported figures
- CABA's LTM Mar 2026 weighted avg shares of 94.61M shares is the 5th highest of the 11 companies compared; the peer median is 85.16M shares.
- Its year-over-year change of +91.6% is the 2nd highest of 11, against a peer median of +20.5%.
- Over three fiscal years its annual growth of +51.6% compares with a peer median of +15.4%.
| Company | Period | LTM | YoY | 3-year CAGR |
|---|---|---|---|---|
| LTM Mar 2026 | 225.47M | +9.3% | +15.5% | |
| LTM Mar 2026 | 167.44M | +37.1% | +15.3% | |
| FY2025 | 145.58M | +21.3% | +19.1% | |
| LTM Mar 2026 | 104.77M | +19.6% | +13.7% | |
| LTM Mar 2026 | 94.61M | +91.6% | +51.6% | |
| LTM Mar 2026 | 90.28M | +9.3% | +8.9% | |
| LTM Mar 2026 | 80.03M | -5.4% | -0.7% | |
LXEOLexeo Therapeutics, Inc. Common Stock | LTM Mar 2026 | 65.52M | +98.2% | +28.7% |
| LTM Mar 2026 | 49.43M | +35.6% | +23.7% | |
| LTM Mar 2026 | 48.56M | +12.5% | +19.7% | |
| LTM Mar 2026 | 18.01M | +34.2% | +11.4% | |
| Peer median (excluding CABA) | 85.16M | +20.5% | +15.4% | |
Competitors are the stored peer set for CABA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 0 | 0 |
| Gross Margin | — | — | — | — | — |
| Research & Development | 32.49M | 39.3M | 55.42M | 97.2M | 142.67M |
| Selling, General & Admin | 13.82M | 14.84M | 19.24M | 27.94M | 29.57M |
| Operating Expenses | 46.31M | 54.14M | 74.66M | 125.14M | 172.24M |
| Depreciation & Amortization | 733K | 1.18M | 1.43M | 1.71M | 1.65M |
| EBITDA | (45.56M) | (51.8M) | (66.25M) | (113.41M) | (164.21M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (46.31M) | (54.14M) | (74.66M) | (125.14M) | (172.24M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 24K | 1.16M | 6.99M | 10.03M | 6.03M |
| Interest Expense | 0 | 0 | 0 | 748K | 2M |
| Other Income / Expenses | 24K | 1.16M | 6.99M | 9.28M | 4.39M |
| Income Before Tax | (46.29M) | (52.98M) | (67.68M) | (115.86M) | (167.86M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (46.29M) | (52.98M) | (67.68M) | (115.86M) | (167.86M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (1.80) | (1.81) | (1.65) | (2.34) | (1.64) |
| EPS (Diluted) | (1.80) | (1.81) | (1.65) | (2.34) | (1.64) |
| Weighted Avg Shares | 25.74M | 29.34M | 40.95M | 49.52M | 102.26M |
| Weighted Avg Shares (Diluted) | 25.74M | 29.34M | 40.95M | 49.47M | 102.26M |
Cabaletta Bio, Inc.
NASDAQ:CABA
Intrinsic Alpha fair value
Locked
Current Price
$1.06
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.